Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets
Natural gums and mucilage have been widely explored as pharmaceutical excipients. The goal of this study was to extract mucilage from the leaves of Aloe barbadensis Miller and to study its functionality as an excipient in pharmaceutical sustained-release tablet formulations.


Pharmaceutical Technology


20. M.E. Aulton, Pharmaceutics: The Science of Dosage Form Design, (Churchill Livingstone, London, 2nd ed.), pp. 133–135.

21. Ministry of Health and Family Welfare, Government of India. Indian Pharmacopoeia (The Controller of Publications, New Delhi, 4th ed., 1996), pp. A-114–116.

22. S.B Gilbert and R.A. Neil, "Tablets" in The Theory and Practice of Industrial Pharmacy, L. Lachman, H.A. Libermann, and J.L. Kanig Eds., (Varghese Publishing House, Bombay, India 3rd ed., 1987), pp. 293–344.

23. R. Ilango et al., "In-vitro Studies on Buccal Strips of Glibenclamide using Chitosan," Indian J. Pharm. Sci. 59 (5), 232–235 (1997).

24. P. Colombo et al., "Drug Release Modulation by Physical Restriction of Matrix Swelling," Int. J. Pharm. 63 (1), 43–48 (1990).

25. P.D. Bharadia and M.C. Gohel, "Formulation and Evaluation of Diclofenac Sodium Modified Release using Ispaghula Husk," The Indian Pharmacist 5 (51), 92–96 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here